scispace - formally typeset
B

Barbara Wollenberg

Researcher at Technische Universität München

Publications -  195
Citations -  2893

Barbara Wollenberg is an academic researcher from Technische Universität München. The author has contributed to research in topics: Medicine & Head and neck squamous-cell carcinoma. The author has an hindex of 25, co-authored 142 publications receiving 2384 citations.

Papers
More filters
Journal Article

Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing

TL;DR: It is demonstrated here that the activation of both T lymphocytes and accessory cells leads to production of immunomodulating cytokines like IL-1beta,IL-2, IL-6, Il-12, and DC-CK1, and therefore this new class of bsAb elicits excellent antitumor activity in vitro even without the addition of exogenous IL-2.
Journal ArticleDOI

Cytokines in head and neck cancer

TL;DR: The better understanding of secretion and regulation pathways of immune suppressive and proangiogenic cytokines in HNSCC is essential to increase the clinical perspective of this tumor type with respect to an immunomodulatory intervention in patients with HNS CC.
Journal ArticleDOI

Application of the Vibrant Soundbridge to unilateral osseous atresia cases.

TL;DR: The objective of this research is to evaluate the active middle ear implant, the Vibrant Soundbridge® (VSB), for hearing rehabilitation of patients with unilateral osseous aural atresia.
Journal ArticleDOI

Isolation and Characterization of Adult Stem Cells from Human Salivary Glands

TL;DR: This study is the first report on the isolation and differentiation of stem cells from adult human parotid glands that share many characteristics with MSCs, and makes salivary gland-derived stem cells a promising source for future applications in regenerative medicine.
Journal ArticleDOI

Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha.

TL;DR: It is demonstrated that tumour‐derived prostaglandin E2 (PGE2) and transforming growth factor‐β (TGF‐β) increase interleukin‐8 (IL‐8) but synergistically inhibit interferon‐α (IFN‐α) and tumour necrosis factor (TNF) production of Toll‐like receptor 7 (TLR7)‐ and Toll‐ like receptor 9 (TLr9)‐stimulated PDC.